El interés en corto de Kazia Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Kazia Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Kazia Therapeutics (NASDAQ:KZIA) Bolsa, Informe de interés en corto

Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors.

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics Ltd

WIIM

FANG

Diamondback Energy shares are trading higher after Benchmark maintained a Buy rating on the stock and raised its price target from $154 to $195.

Groupon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grpn#NASDAQ">GRPN</a>) has seen its stock decline 25.2% year to date (YTD) against the Zacks Internet-Commerce industry&#39;s growth of 22.9%, the broader retail sector&#39;s return of 19.4% and the S&amp;P 500 index&#39;s rally of 20%.
GRPN, which has emerged as a two-sided global marketplace company, has been suffering from its weakening momentum in the international market. Unexpected site stability issues related to its cloud migration project have also been heavily affecting the company&#39;s performance.
Groupon&#39;s business model makes it heavily dependent on daily deals, which is a major headwind. Since most of the offerings are consumer discretionary products, demand is heavily dependent on macroeconomic conditions. Given this, the ongoing market uncertainties, persistent inflation, looming recessionary fears, changing consumer demand and spending patterns are dampening the company&#39;s near-term prospects.
<h2>Year-to-Date Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/40/80256.jpg?v=610392595" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
GRPN&#39;s bearish guidance is a negative. For 2024, the company expects revenues between $495 million and $515 million, indicating a year-over-year change between (4%) and 0%. The Zacks Consensus Estimates for 2024 revenues is pegged at $514.51 million, implying a year-over-year decline of 0.1%.
The company operates in a highly competitive market, wherein it faces significant competition from the likes of Yelp (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yelp#NYSE">YELP</a>), Rakuten, Travelzoo (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tzoo#NASDAQ">TZOO</a>) and Wowcher.
Groupon&#39;s solid momentum in its marketplace platform and strength in its e-commerce business model are major positives. Its large-scale global operations and growing relationship with third-party merchants reflect the company&#39;s upside potential, which bodes well for its long-term prospects.
Given the YTD dip in GRPN shares, investors are questioning whether this is the right time to buy the stock. Let us explore this in more detail.
<h2>E-commerce Strategies to Drive GRPN&#39;s Prospects</h2>
Groupon, through its e-commerce platform, offers numerous deals that can be accessed by users anywhere at any time.
GRPN&#39;s strategy to build a trusted marketplace, wherein customers purchase local services and experiences, is a major positive. For this, the company&#39;s growing efforts to build long-term relationships with local merchants to strengthen its inventory selection remain noteworthy.
It strives to deliver enhanced customer experience through inventory curation and improved convenience in order to boost purchase frequency on its platform.
To strengthen the platform, the company is lifting restrictions on its deeply discounted deals and is enabling customers to purchase such deals more than once to improve the frequency and drive growth in billings.
Growing momentum across the North America region has been driving growth in the company&#39;s Local segment, which contributes the most to GRPN&#39;s total revenues and remains crucial for its e-commerce business. In second-quarter 2024, Local revenues were $114.1 million (92% of total revenues), driven by North America Local revenues, which grew 7.3% year over year.
Groupon&#39;s long-term prospects rest upon its ability to offer more innovative products and build a broader Local e-commerce platform.&nbsp;
The company&#39;s strengthening supply drivers for North America Local are tailwinds. Groupon is witnessing growing traction among large enterprise merchants, thanks to expanding 
relationships with existing partners, and the addition of brands to the platform.
GRPN&#39;s initiatives to remove lower-quality deals from its site that do not align with the brand promise are a plus. Groupon also made substantial progress in curating its deals, with an enhanced presentation, improved deal copy and better images.
Solid demand for family-friendly activities, ranging from trampoline parks and bowling alleys to amusement parks and water parks, is another positive. The company expects to see continued growth in these areas in the days ahead.
Growing momentum in Groupon&#39;s latest initiative called Flash Sale, which was tested first in first-quarter 2024 with one enterprise merchant, is noteworthy. The Flash Sale concept boosted its performance and, hence, the company expanded this program in second-quarter 2024, running over a dozen flash sales with existing merchants to drive performance and boost engagement on its site. Although the initiative is fresh and new, it reflects the company&#39;s potential to expand its business by developing products to cross-sell and up-sell into its supply base.
Groupon&#39;s AI initiative is a major plus. AI integration has enabled it to improve the copywriting of its deals and deal creation process. It leverages AI on projects in product and engineering to improve deal recommendation and quality assurance. Improvements in enterprise sales organization and process changes, combined with value proposition changes, continue to contribute to growth in its enterprise accounts.
<h2>Upward Earnings Trend Paints Bright Picture for GRPN</h2>
Investors are turning bullish about Groupon&#39;s upside potential, which is reflected in the upward revisions in earnings estimates.
For 2024, the Zacks Consensus Estimate for earnings is pegged at 47 cents per share, whereas the company reported a 2023 loss of 52 cents. The estimate has been revised upward by 56.7% over the past 60 days.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80258.jpg?v=1264508241" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h2>Attractive Valuation: A Silver Lining for GRPN</h2>
Groupon is currently trading at a discount with a forward 12-month Price/Sales of 0.7X compared with the industry&#39;s 1.72X and lower than the median of 0.84X. This indicates an excellent opportunity for investors.
GRPN also has a Value Score of B, which is hard to ignore.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/56/80257.jpg?v=1027816364" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h2>Conclusion</h2>
Despite near-term hurdles, Groupon&#39;s strong marketplace, robust e-commerce business model, growing merchants base and solid supply drivers present a solid investment opportunity for growth-seeking investors.
Its attractive valuation and Growth Score of A make a compelling case for buying the GRPN stock at its current levels.
Groupon sports a Zacks Rank #1 (Strong Buy) at present.
<a href="https://www.zacks.com/stock/news/2345645/groupon-shares-decline-25-2-ytd-should-you-buy-the-dip-right-now?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2345645">To read this article on Zacks.com click here.</a>

Earnings

Mid Cap

News

Guidance

Retail Sales

Small Cap

Markets

Analyst Ratings

Tech

Trading Ideas

GRPN

TZOO

YELP

Groupon Shares Decline 25.2% YTD: Should You Buy the Dip Right Now?

Texas Attorney General Ken Paxton has filed a lawsuit against several major insulin manufacturers and pharmacy benefit managers (PBMs), alleging a conspiracy to <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40560002/governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-r" rel="noreferrer noopener">inflate insulin prices</a>.
The <a target="_blank" href="https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-sues-big-pharma-drug-manufacturers-and-pharmacy-benefit-managers" rel="noreferrer noopener">lawsuit</a> targets pharmaceutical companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and PBMs, including Cigna Corp's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) Express Scripts and CVS Health Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) CVS Pharmacy, accusing them of engaging in an unlawful scheme to raise insulin prices.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices</a>.
According to the lawsuit, insulin manufacturers artificially raised the prices of their drugs while paying PBMs a significant, undisclosed portion in return for preferred placement in PBM offerings.
The PBMs allegedly rewarded the manufacturers with the highest list prices by giving their products preferred status while excluding more affordable alternatives.
These insulin drugs, which cost manufacturers less than $2 to produce, were introduced in the late 1990s at $20 per vial. However, prices have now soared to between $300 and $700 per vial.
Over the past decade, some manufacturers have raised insulin prices by as much as 1,000%.
Paxton expressed outrage over the alleged scheme, stating, "This is a disturbing conspiracy by which pharmaceutical companies were intentionally and artificially inflating the price of insulin. Big Pharma insulin manufacturers and PBMs worked together to take advantage of diabetes patients and drive prices as high as they could." He vowed to hold these companies accountable for their actions.
The complaint further claims that while PBMs have publicly positioned themselves as entities working to reduce drug prices and improve treatment access, their actions tell a different story.
The lawsuit argues that the PBMs have colluded with insulin manufacturers to manipulate the market for their financial gain, all at the expense of Texas diabetics and healthcare payors.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171469/uber-avride-join-forces-for-autonomous-delivery-partners-with-enso-for-low-emission-ev-tires" target="_blank" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a></li>
</ul>
Photo by towfiqu barbhuiya via unsplash

Government

Large Cap

Health Care

Legal

General

Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%

Deutsche Bank analyst Scott Deuschle maintains Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) with a Buy, raising the <a target="_blank" href="https://www.benzinga.com/quote/LMT/analyst-ratings" rel="noreferrer noopener">price forecast from&nbsp;$600&nbsp;to&nbsp;$620.</a>
The analyst suggests that Lockheed Martin likely prefunds its pension in the fourth quarter, although the company may delay a formal announcement until after it&#8217;s completed.
Deuschle adds that the associated debt issuance for this funding is expected to occur sooner.
The analyst forecasts third-quarter EPS of $6.70, approximately 4% above the Street&#8217;s estimate of $6.47.
Deuschle sees revenue of around $17.4 billion, which is $100 million below the Street&#8217;s expectation, as the analyst incorporates the $500 million F-35 contract delay impact at Aeronautics, which is not fully reflected in the Street&#8217;s projections.
The analyst identifies the greatest upside potential in Space, noting that underlying margins excluding United Launch Alliance (ULA)&nbsp;are expected to decline significantly in the second half.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41012117/lockheed-martins-unit-secures-contract-for-ch-53k-gearbox-assemblies" rel="noreferrer noopener">Lockheed Martin&#8217;s Unit Secures Contract for CH-53K Gearbox Assemblies</a>
This outlook seems conservative, considering that two major contracts—Orion and OPIR—are entering a highly mature phase of their production lifecycle.
The analyst projects a third-quarter revenue beat, which may lead to an upward revision of the full-year revenue guidance, potentially nearing $72 billion.
Deuschle also sees a 1%-2% increase to the midpoint of the full-year segment EBIT guidance, especially if EBIT upside is realized in Space during the third quarter, as seen in the first half.
The analyst sees the company offer some indication for 2025 financial trends.
Given the firm&#8217;s conservative track record, the analyst sees the company is likely to project approximately 3% revenue growth and reiterates its target for 10-20 basis points of margin expansion.
Deuschle also projects a dividend increase announcement ahead of earnings, and the buyback authorization will likely be topped up.
Price Action: LMT shares are trading lower by 0.29% to $601.79 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019" target="_blank" rel="noreferrer noopener">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></li>
</ul>

Analyst Color

Equities

Price Target

Reiteration

Lockheed Martin's Greatest Upside Potential Is In Space: Analyst Sees Dividend Hikes, Buyback Top Ups

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is gearing up for a $783 million debt sale, coinciding with a busy October that features the highly <a href="https://www.benzinga.com/news/24/09/40808924/tesla-robotaxi-event-to-be-held-in-los-angeles-on-1010-says-senior-company-exec-existing-shareholder">anticipated Robotaxi Day.</a>
What Happened: Tesla, which recently<a href="https://www.benzinga.com/news/24/10/41141444/tesla-stock-plunges-3-despite-q3-deliveries-exceeding-consensus-and-growing-year-over-year"> reported third-quarter delivery</a> and production figures, could price its debt sale as early as next week.
The debt sale, which is being run by Societe Generale, would see Tesla provide the backing of prime borrowers' car leases, as reported by <a href="https://www.bloomberg.com/news/articles/2024-10-03/tesla-plans-783-million-debt-sale-backed-by-prime-leases?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>.
According to the report, this would mark Tesla&#8217;s second financing this year. Tesla raised $750 million in March.
By leveraging its car leases, Tesla would join other automakers in using asset-backed securities as a tool to finance future growth.
Tesla has previously used asset-backed securities for funding, but not as much as its U.S. automotive rivals, the report said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
 What's Next: The financing news follows Tesla&#8217;s third-quarter delivery figures and comes ahead of several key October catalysts, which could lead to significant volatility in the company&#8217;s stock.
Tesla will host its Robotaxi Day on Oct. 10 and report third-quarter financial results on Oct. 23, which mark two of the biggest company events in the last three months of the calendar year.
The company will<a href="https://www.benzinga.com/news/24/09/41027049/tesla-returns-to-paris-motor-show-for-first-time-in-6-years-cybertruck-to-be-featured-will-elon-musk"> also exhibit multiple models</a>, including the Cybertruck, at the Paris Auto Show from Oct. 14 to Oct. 20. This marks Tesla's first appearance at the auto show in six years.
TSLA Price Action: Tesla stock was down 4% to $238.26 on Thursday, compared to a 52-week trading range of $138.80 to $271.00. It is down 4.1% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/10/41166723/how-many-evs-has-tesla-delivered-produced-each-quarter-a-look-at-the-results-since-2019">How Many EVs Has Tesla Delivered, Produced Each Quarter? A Look At The Results Since 2019</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

TSLA

Tesla Uses Auto Leases To Back $783M Debt Sale: Report

FFWM

First Foundation shares are trading higher after the company announced it will be reclassifying $1.9 billion from its multifamily portfolio from loans held to maturity to loans held for sale.

Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) owned streaming platform AppleTV+ is one of the smaller players in<a href="https://www.benzinga.com/topic/streaming"> the streaming market.</a>
When it comes to star power, Apple has landed some big names. A movie with two of the biggest actors around could help boost the future outlook.
What Happened: With ballooning budgets and tough decisions on whether to play movies in cinemas, and then stream them on AppleTV+, the technology giant recently announced it would <a href="https://www.benzinga.com/news/24/09/41073117/apples-reviews-strategy-cuts-film-budgets-after-blockbuster-spend-whats-next-for-apple-tv">scale back movie budgets.</a>
That decision comes after Apple recently debuted "Wolfs" in a limited theatrical release ahead of its Sept. 27 streaming premiere on AppleTV+.
While most films starring George Clooney and Brad Pitt, would command a premium budget and likely see a strong box office run, the "Wolfs" stars have denied getting a reported $35 million each and said they were paid less for the film
After originally planning on releasing the movie widely in movie theaters, Apple made the decision to switch to a limited run ahead of the streaming premiere.
The decision may have paid off with Apple saying "Wolfs" is now the most viewed movie in AppleTV+ history, without providing a specific figure.
"Wolfs" helped boost viewership on AppleTV+ by 30% week-over-week after the movie's premiere according to a report from <a href="https://deadline.com/2024/10/george-clooney-brad-pitt-wolfs-most-viewed-movie-in-apple-tv-history-1236105000/">Deadline</a>.
The film, which premiered at the Venice Film Festival, has already been green lit for a sequel by Apple, with the film's writer and director Jon Watts returning.
"When George, Brad and Jon approached us with the idea for ‘Wolfs,' it was an easy call – a crackling, fun movie starring two Oscar winners who everyone knows are iconic together," Apple Original Films' head of features Matt Dentler said.
Dentler said AppleTV+ could be the "home for the world's most talented artists to create and deliver their best work" and the audience viewership has been existing.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It Matters: Apple TV+ was launched on Nov. 1, 2019. It marked Apple&#8217;s entry into the competitive streaming market, which is <a href="https://www.benzinga.com/news/24/04/38337256/netflix-once-again-evolved-and-eclipsed-its-streaming-war-rivals">dominated by </a>Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
While the decision not to run the movie in theaters may have been tough for Apple and left money on the table, it likely means a boost to streaming viewership figures and potentially an uptick in subscriber.
Apple has <a href="https://www.benzinga.com/24/03/37558754/apples-1b-gamble-on-3-blockbusters-analyzing-box-office-results-streaming-impact-and-oscar-nominatio">seen recent success </a>at the Academy Awards with "CODA," which won a historic Oscar for Best Picture at the 94th Academy Awards. 
Other Apple-produced movies also saw theatrical releases. They include:
<ul>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt5537002/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Killers of the Flowers Moon</a>&#8220;: $67.9 million domestic, $89 million international, $156.9 million global</li>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt13287846/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Napoleon</a>&#8220;: $61.5 million domestic, $159.5 million international, $221 million global</li>
<li>&#8220;<a href="https://www.boxofficemojo.com/title/tt15009428/?ref_=bo_se_r_1" target="_blank" rel="noreferrer noopener">Argylle</a>&#8220;: $44.2 million domestic, $48.2 million international, $92.5 million global</li>
</ul>
In total, the three movies cost around $700 million for Apple and grossed $470.4 million worldwide, according to BoxOfficeMojo.
While the box office figures didn't break even on costs, a studio source told Variety that both "Killers of the Flower Moon" and "Napoleon" were profitable thanks to other revenue streams.
Netflix, in contrast, rarely uses the theater distribution model for its films. But Apple has adopted a strategy of premiering its major films in theaters before offering them exclusively on its streaming platform, Apple TV+.
This model helps Apple recover some of its costs and could also help the company be a staple for award shows that require a theatrical run.
Apple finds itself in a difficult place with the need to spend more on content to boost subscribers, but also having less to spend on movies and content due to a smaller subscriber base. With the parent company a cash cow, Apple may be able to maintain losses for its streaming business if it chooses to, but could also push for a larger focus on profits.
Reports say Apple is considering<a href="https://www.benzinga.com/general/entertainment/24/07/40014040/apple-to-follow-netflix-disney-ad-supported-appletv-streaming-plan-could-launch-soon"> launching an ad-supported </a>streaming plan soon, which could help alleviate some of the revenue concerns and bring in more money to be spent on content.
The company&nbsp;<a href="https://www.benzinga.com/news/23/06/32764885/lionel-messi-joins-mls-in-surprise-move-heres-how-apple-could-have-played-into-decision-to-join-davi" target="_blank" rel="noreferrer noopener">previously acquired the rights</a>&nbsp;to Major League Soccer and select Major League Baseball games. The MLS bet paid off with superstar&nbsp;Lionel Messi&nbsp;joining the league and Apple&nbsp;<a href="https://www.benzinga.com/news/23/08/33737512/lionel-messis-inter-miami-stint-leads-to-explosive-surge-in-mls-streaming-subscribers-double" target="_blank" rel="noreferrer noopener">seeing a boost</a>&nbsp;in subscribers to the platform.
Apple will release "Blitz" in select theaters on Nov. 1 with a streaming premiere on AppleTV+ on Nov. 22. The company also has "F1," which stars Pitt, opening in theaters on June 25, 2025.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100324">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Image: Shutterstock

Entertainment

AAPL

NFLX

Apple TV+ Scores Biggest Streaming Movie In History Thanks To George Clooney, Brad Pitt

Nike (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares fell after the Q1 report, which opened an opportunity for investors. The fall is due to numerous factors, including weaker-than-expected results, revoked guidance, and a CEO transition that is ultimately expected to turn the company around. The takeaway is that Nike faces headwinds and has a long road to recovery, but market support remains firm, and recovery is expected. The question is if now is the right time to buy or if the stock will make a deeper correction before the rebound begins.
The analysts are trimming targets but have yet to make any downgrades. The 19 MarketBeat tracks have the stock pegged at a Moderate Buy and trading near a floor in the low $70s. With this dynamic in play, the market will likely bottom soon and begin to rebuild the base. The critical drivers for the action going forward will be a recovery in wholesales and product innovation, the primary reasons for the company&#39;s weakness today. Nike&#39;s leaning into direct-to-consumer sales eroded wholesaler support, exacerbating market share losses related to innovation.&nbsp;
Nike did not make any significant product innovations for years until 2024, losing market share to start-ups like On Holdings (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) and legacy shoemakers like Adidas (OTC: <a class="ticker" href="https://www.benzinga.com/stock/adddf#OTC">ADDDF</a>) and Deckers Outdoors (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/deck#NYSE">DECK</a>). On Holdings is growing at an industry-leading double-digit pace while Nike flounders in contraction. Even so, the new Nike pipeline depends on updates to existing Air technology, athlete partnerships to drive product changes, and streamlined production, which may not yield results quickly. The best estimates are for the changes to take effect in early 2026, more than eighteen months away.&nbsp;
<h2>Nike Had a Tough Quarter, But Not a Bad One</h2>
Nike had a tough time in Q1, but the business remains profitable, producing positive cash flow sufficient to sustain balance sheet quality and capital returns. The company reported $11.6 billion in net revenue, down 10.4% compared to last year, falling short of the consensus estimates but beating the bottom line. Revenue was impacted by weakness in Nike and Converse brands, DTC, and wholesales, with a contraction in the core footwear and apparel categories. Equipment is the single area of strength, up 34%, aiding bottom-line results.&nbsp;
The margin news is also mixed, with gross margin and selling, general, and administrative expenses (SG&amp;A) improving but offset by increased sales and tax expenses. The takeaway is that net income is down 28% year over year, and the diluted GAAP EPS is 26% but well above forecasts, reflecting operational improvements and quality. The net result is $0.70 in GAAP EPS, which is more than 3500 basis points above consensus, with margin quality expected to continue in the coming quarters.&nbsp;
The details that spooked the market are the retracted full-year guidance and delayed investor day conference, which brings an element of uncertainty to the outlook with the CEO change due soon. As it is, the company expects Q2 revenue to be down 8% to 10%, putting the H1 outlook in alignment with the prior forecast.&nbsp;
<h2>No Red Flags on Nike&#39;s Strong Balance Sheet: Capital Returns Can Run</h2>
As troubled as Nike is, the company produced a positive cash flow quarter and improved its balance sheet while sustaining dividends and share repurchases. The share repurchases topped $1 billion for the quarter, helping to reduce the average count by 2.7%, and will likely continue as the fiscal year progresses.&nbsp;
The dividend is also safe at roughly 50% of the quarterly earnings. However, the pace of annual increase will likely slow from double-digits into the low single-digits until growth is reinvigorated. Regarding the balance sheet, cash and assets are up compared to last year, and debt and equity are relatively flat, leaving the company in a net-cash position relative to its debt, with leverage low at 0.6x equity. Nike has work to do but is in a solid financial position, capable of making the necessary moves to achieve its goal.&nbsp;
<img alt="Nike NKE stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241002091343_chart-nke-1022024.png" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/originals/nikes-post-earnings-drop-presents-a-buying-opportunity/">Nike&#39;s Post-Earnings Drop Presents a Buying Opportunity</a>&quot; first appeared on MarketBeat.

Dividends

ADDDF

DECK

ONON

Nike's Post-Earnings Drop Presents a Buying Opportunity

Investors with a lot of money to spend have taken a bullish stance on Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CELH, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 13 uncommon options trades for Celsius Holdings.
This isn't normal.
The overall sentiment of these big-money traders is split between 46% bullish and 38%, bearish.
Out of all of the special options we uncovered, 7 are puts, for a total amount of $376,568, and 6 are calls, for a total amount of $212,218.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $17.5 to $130.0 for Celsius Holdings during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Celsius Holdings options trades today is 868.0 with a total volume of 2,525.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Celsius Holdings's big money trades within a strike price range of $17.5 to $130.0 over the last 30 days.
<h3>Celsius Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983154_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$100.0</td>
<td>$98.35</td>
<td>$100.0</td>
<td>$130.00</td>
<td>$90.0K</td>
<td>218</td>
<td style="text-align: right;">9</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.3</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$30.00</td>
<td>$73.0K</td>
<td>761</td>
<td style="text-align: right;">207</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.75</td>
<td>$6.65</td>
<td>$6.75</td>
<td>$40.00</td>
<td>$59.4K</td>
<td>2.4K</td>
<td style="text-align: right;">219</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$5.5</td>
<td>$5.4</td>
<td>$5.42</td>
<td>$35.50</td>
<td>$54.0K</td>
<td>37</td>
<td style="text-align: right;">200</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$5.45</td>
<td>$5.2</td>
<td>$5.31</td>
<td>$35.50</td>
<td>$53.1K</td>
<td>37</td>
<td style="text-align: right;">100</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages (including those that are naturally caffeinated with stevia), Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
In light of the recent options history for Celsius Holdings, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Celsius Holdings</h3>
<ul>
<li>With a volume of 4,035,346, the price of CELH is down -0.66% at $30.25. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Celsius Holdings</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $42.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Celsius Holdings, maintaining a target price of $47. 
&#x2A; An analyst from Roth MKM persists with their Buy rating on Celsius Holdings, maintaining a target price of $45. 
&#x2A; Maintaining their stance, an analyst from Roth MKM continues to hold a Buy rating for Celsius Holdings, targeting a price of $43. 
&#x2A; An analyst from B of A Securities has decided to maintain their Underperform rating on Celsius Holdings, which currently sits at a price target of $26. 
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Celsius Holdings with a target price of $51. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

CELH

Looking At Celsius Holdings's Recent Unusual Options Activity

Financial giants have made a conspicuous bullish move on Hims &amp; Hers Health. Our analysis of options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) revealed 39 unusual trades.
Delving into the details, we found 58% of traders were bullish, while 28% showed bearish tendencies. Out of all the trades we spotted, 11 were puts, with a value of $756,530, and 28 were calls, valued at $3,089,081.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $30.0 for Hims &amp; Hers Health over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Hims &amp; Hers Health options trades today is 2581.74 with a total volume of 69,554.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Hims &amp; Hers Health's big money trades within a strike price range of $10.0 to $30.0 over the last 30 days.
<h3>Hims &amp; Hers Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983149_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$2.25</td>
<td>$2.1</td>
<td>$2.2</td>
<td>$20.00</td>
<td>$1.0M</td>
<td>6.1K</td>
<td>5.0K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.8</td>
<td>$6.7</td>
<td>$6.8</td>
<td>$15.00</td>
<td>$152.3K</td>
<td>2.8K</td>
<td>947</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.05</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$13.00</td>
<td>$150.0K</td>
<td>1.4K</td>
<td>2.7K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.5</td>
<td>$6.4</td>
<td>$6.5</td>
<td>$15.00</td>
<td>$139.7K</td>
<td>2.8K</td>
<td>262</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.0</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$20.00</td>
<td>$125.0K</td>
<td>2.3K</td>
<td>640</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Having examined the options trading patterns of Hims &amp; Hers Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Hims &amp; Hers Health's Current Market Status</h3>
<ul>
<li>With a trading volume of 22,353,251, the price of HIMS is down by -10.18%, reaching $17.02.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 32 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from B of A Securities has decided to maintain their Buy rating on Hims &amp; Hers Health, which currently sits at a price target of $20. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Hims &amp; Hers Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Check Out What Whales Are Doing With HIMS

Investors with a lot of money to spend have taken a bullish stance on ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ZIM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for ZIM Integrated Shipping.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 33%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $95,507, and 6 are calls, for a total amount of $311,252.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $5.0 to $25.0 for ZIM Integrated Shipping during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ZIM Integrated Shipping's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ZIM Integrated Shipping's substantial trades, within a strike price spectrum from $5.0 to $25.0 over the preceding 30 days.
<h3>ZIM Integrated Shipping 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727983144_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.0</td>
<td>$16.95</td>
<td>$17.0</td>
<td>$5.00</td>
<td>$93.5K</td>
<td>78</td>
<td>55</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.79</td>
<td>$0.66</td>
<td>$0.66</td>
<td>$25.00</td>
<td>$66.0K</td>
<td>15.5K</td>
<td>2.1K</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$1.95</td>
<td>$1.76</td>
<td>$1.95</td>
<td>$24.00</td>
<td>$58.5K</td>
<td>792</td>
<td>316</td>
</tr>
<tr>
<td>ZIM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$0.97</td>
<td>$0.0</td>
<td>$0.91</td>
<td>$22.00</td>
<td>$39.0K</td>
<td>97</td>
<td>432</td>
</tr>
<tr>
<td>ZIM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$1.92</td>
<td>$1.46</td>
<td>$1.69</td>
<td>$22.50</td>
<td>$33.8K</td>
<td>5.6K</td>
<td>200</td>
</tr>
</tbody>
</table>

<h3>About ZIM Integrated Shipping</h3>
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
After a thorough review of the options trading surrounding ZIM Integrated Shipping, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of ZIM Integrated Shipping</h3>
<ul>
<li>With a trading volume of 4,796,348, the price of ZIM is up by 1.24%, reaching $23.7.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 41 days from now.</li>
</ul>
<h3>Expert Opinions on ZIM Integrated Shipping</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $17.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from Jefferies lowers its rating to Hold with a new price target of $25. 
&#x2A; In a cautious move, an analyst from JP Morgan downgraded its rating to Underweight, setting a price target of $10. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for ZIM Integrated Shipping, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Decoding ZIM Integrated Shipping's Options Activity: What's the Big Picture?

Oil is trading more than 5% higher Thursday on the heels of President Joe Biden&#8216;s statement that the U.S. spoke with Israel about a possible attack on Iran's oil facilities.
"We're in discussions about that,&#8221; Biden said during an interaction with reporters. 
Biden seemingly indicated he wasn&#8217;t partial to the idea of striking at Iran&#8217;s oil facilities, before cutting himself off: &#8220;I think that would be a little&#8230; anyway.&#8221; See video below.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Biden: Discussing Israeli strikes on Iran oil facilities &#x7C; AJ #shorts" width="500" height="281" src="https://www.youtube.com/embed/InF5MnsXAt0?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
When one reporter asked whether Biden would &#8220;allow&#8221; Israel to retaliate against Iran, Biden swiftly corrected him: &#8220;First of all, we don&#8217;t &#8216;allow&#8217; Israel. We advise Israel.&#8221;
<a href="https://www.benzinga.com/news/23/10/35136071/israel-under-siege-unprecedented-hamas-attack-sparks-intense-clashes-netanyahu-says-we-are-at-war">Since Oct. 7, 2023</a>, Israel has been fighting Hamas in Gaza as well as Hezbollah in Lebanon. Both groups are considered terrorist organizations by the U.S. 
See Also: <a href="https://www.benzinga.com/news/24/10/41134015/jd-vance-tim-walz-debate-sets-a-different-tone-candidates-discuss-israel-iran-escalation-immigration">JD Vance, Tim Walz Debate Sets A Different Tone, Candidates Discuss Israel-Iran Escalation</a>
<h3 class="wp-block-heading">Oil And The Israel-Iran Conflict</h3>
Iran is the seventh-largest oil producer in the world. The country, which backs the Hezbollah militant group, exports around half its production abroad. 
China, where <a href="https://www.benzinga.com/markets/asia/24/08/40596334/asia-markets-mixed-europe-gains-crude-oil-falls-on-chinese-demand-concerns-global-markets-today-whil">oil demand is weak</a>, is its main customer.
Since Iran's <a href="https://www.benzinga.com/news/global/24/10/41126038/iran-attacks-israel-with-missiles-middle-east-tensions-escalates-s-p-500-stocks-bitcoin-fall-as-oil">missile attack on Israel</a> on Monday, the price of barrels has fluctuated. As of Oct. 3, the price of West Texas Intermediate (WTI) crude oil is $73.83 per barrel. This reflects a 5.32% increase from the previous day&#8217;s close of $70.10.
The price of Brent crude is approximately $77.76 per barrel. It has fluctuated within a range of $74.33 to $77.58 for the day.
The U.S., which is producing more oil under Biden than any other U.S. presidential administration, has been filling its reserves. The Biden administration acquired an additional <a href="https://www.benzinga.com/markets/eurozone/24/10/41146905/geopolitical-risks-may-be-biggest-threat-to-markets-boe-says">6 million barrels of crude</a> just this week.
It&#8217;s worth noting that ongoing violence in the Middle East puts the Straits of Hormuz at risk. A third of tanker traffic and a fifth of LNG frozen gas is transported through that passageway. 
The U.S. and its allies are likely determined to keep the Strait open due to its strategic importance. Any attempt to block the Strait could provoke military intervention.
Iran controls much of the northern coastline of the Strait and has previously threatened to block the passage in response to sanctions or conflicts with Western countries. 
<h3 class="wp-block-heading">Market Reaction</h3>
So far, market reaction to the Middle East conflict is relatively mute compared to February 2022 when Russia invaded Ukraine.
At the time, the oil market reacted with significant volatility and disruption, leading to a sharp rise in global prices. 
Brent crude, the global benchmark, surged above $100 per barrel for the first time since 2014, and by March 2022, it had briefly spiked to $139 per barrel, near the all-time high.
Oil-related exchange-traded funds, or ETFs, were trending up at last check Thursday afternoon. Here&#8217;s where they stand: 
<ul>
<li>United States Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>) is up 4.05% to $75.71</li>
<li>Invesco DB Oil Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBO#NYSE">DBO</a>) is up 4.08% at $15.06</li>
<li>SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) is up 3.1% at $139.56</li>
<li>Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) up 1.65% at $92.22</li>
<li>ProShares Ultra Bloomberg Crude Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UCO#NYSE">UCO</a>) is up 6.59% at $28.81</li>
<li>VanEck Vectors Oil Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OIH#NYSE">OIH</a>) is up 1.89% at $297.58</li>
</ul>
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/10/41170128/jobs-report-preview-could-september-labor-data-shift-feds-interest-rate-path">Jobs Report Preview: Could September Labor Data Shift Fed&#8217;s Interest Rate Path?</a></li>
</ul>
Image: Shutterstock

Regulations

Sector ETFs

Commodities

Politics

Global

ETFs

Oil Prices Rally: Biden Confirms US 'Discussions' With Israel About Striking Iran Facilities

Deutsche Bank analyst Scott Deuschle changed price targets and presented earnings previews for major Aerospace companies such as GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>).
The analyst writes that these stocks are well-insulated against end-market challenges and are likely to achieve the largest earnings beats and drive significant upward revisions.
GE Aerospace: The analyst raised the price target to $235 from $212 <a target="_blank" href="https://www.benzinga.com/quote/ge/analyst-ratings" rel="noreferrer noopener">while maintaining a Buy rating</a>.
Deuschle expects a 9% EPS beat in their base case and a 15% beat in the blue sky scenario for the third quarter.
In both cases, the analyst anticipates an increase in 2024 guidance, with a potential 7% EBIT rise if the blue sky scenario occurs.
Strong CSA collections from the summer flying season could drive free cash flow (FCF) above expectations, leading to an increase in FCF guidance, adds the analyst.
Overall, Deuschle says that they are optimistic ahead of the earnings release due to the potential for a significant beat and raise this quarter.
Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40986267/ge-aerospace-takes-flight-with-ai-wingmate-boosts-innovation-employee-productivity-with-microsof" rel="noreferrer noopener">GE Aerospace Takes Flight With AI Wingmate: Boosts Innovation, Employee Productivity With Microsoft&#8217;s Azure AI</a>
Howmet: The analyst raised the price target to $125 from $106 while <a target="_blank" href="https://www.benzinga.com/quote/hwm/analyst-ratings" rel="noreferrer noopener">maintaining a Buy rating</a>.
The analyst writes that the base case estimates third-quarter EPS at $0.68, above the Street&#8217;s $0.66, with a roughly 2% midpoint guidance increase.
The analyst cited upside drivers such as pricing strategies, strong execution allowing shipments above long-term agreement caps, and earlier-than-expected generation 2 LEAP HPT blade shipments.
Deuschle expects HWM to guide 2025 revenue in line with the Street (+10%), which could trigger further positive revisions, given a higher 2024 base and likely surprises in Engine Products EBITDA margins.
Read Next: <a target="_blank" href="https://www.benzinga.com//node/41171469" rel="noreferrer noopener">Uber &amp; Avride Join Forces for Autonomous Delivery; Partners With ENSO For Low-Emission EV Tires</a>
For Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), the analyst lowered the price target to $195 from $225 while <a target="_blank" href="https://www.benzinga.com/quote/BA/analyst-ratings" rel="noreferrer noopener">maintaining a Buy rating</a>.
The analyst anticipates a third-quarter free cash flow burn of ($4.0 billion), up from a previous estimate of ($2.4 billion), due to the strike&#8217;s impact on September deliveries and ongoing cash pressures in Boeing&#8217;s Defense segment.
The forecast includes a $1 billion EBIT loss at Boeing Defense Systems (BDS) and a $1.6 billion loss at Boeing Commercial Airplanes (BCA), adds the analyst.
Deuschle says that BCA loss forecast assumes a $1 billion forward loss on the 777X, reflecting delays in entry into service and increased costs related to union negotiations and wage hikes.
Also Read: <a href="https://www.benzinga.com/news/24/10/41170226/boeing-workers-union-says-decision-to-cut-health-care-for-33-000-is-unnecessary-and-cruel" target="_blank" rel="noreferrer noopener">Boeing Workers&#8217; Union Says Decision To Cut Health Care For 33,000 Is &#8216;Unnecessary And Cruel&#8217;</a>
Image via Shutterstock

GE and Howmet Poised for Strong Earnings as Aerospace Sector Stays Resilient: Analyst

The Western Union Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wu#NYSE">WU</a>) inked a deal with the Open Finance company, Khipu, enabling customers to transfer money digitally using any bank account in Chile.
The agreement incorporates Khipu&#39;s technology into Western Union&#39;s mobile app and website. Earlier, customers paying through a bank account had to leave the Western Union app or website and log into their bank&#39;s platform to complete the payment. This step is now removed as a result of the latest integration, allowing the entire transaction to be completed within the Western Union platform. The service is now available via the Western Union Chile app and website.
Western Union has also introduced a special promotion offer with a $0 fee for the first remittance made using the &quot;Online Bank Transfer&quot; option, thereby encouraging customers to explore the new service. The collaboration between WU and Khipu makes sure that cross-border payments can be made faster and more seamlessly by Chile&#39;s customers.
<h2>Benefits of the Recent Move to Western Union</h2>
The recent initiative reflects Western Union&#39;s sincere efforts to establish a solid footprint across the Chilean remittance market.&nbsp;
Moves similar to the latest one are indicative of Western Union&#39;s efforts to align with its global digital expansion strategy, designed to attract more customers through its diverse service offerings. Speedier money transfers brought about by integrating Khipu&#39;s technology into the WU platform are likely to result in the increased usage of its money transfer services. This move is likely to further boost the company&#39;s digital money transfer revenues in the days ahead.
Strategic partnerships with financial service providers and significant investments have enabled Western Union to develop a robust digital platform. This platform&#39;s strength has made it a preferred partner for efficient global money transfers and advancing digitization in underserved regions.
<h2>Western Union&#39;s Stock Price Performance</h2>
Shares of Western Union have dipped 0.7% year to date against the industry&#39;s 8.8% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/af/80259.jpg?v=1602165044" />
Image Source: Zacks Investment Research
<h2>WU&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
WU currently carries a Zacks Rank #2 (Buy).&nbsp;
Some other top-ranked stocks in the Business Services space are Duolingo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/duol#NASDAQ">DUOL</a>), RCM Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcmt#NASDAQ">RCMT</a>) and AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>), each currently sporting a Zacks Rank #1 (Strong Buy).
The bottom line of Duolingo outpaced estimates in each of the last four quarters, the average surprise being 92.09%. The Zacks Consensus Estimate for DUOL&#39;s 2024 earnings is pegged at $1.87 per share, which indicates a more than five-fold increase from the year-ago figure. The consensus mark for revenues implies growth of 38.6% from the year-ago number. The consensus mark for DUOL&#39;s 2024 earnings has moved 7.5% north in the past 60 days.&nbsp;
RCM Technologies&#39; earnings outpaced estimates in three of the trailing four quarters and matched the mark once, the average surprise being 17.49%. The Zacks Consensus Estimate for RCMT&#39;s 2024 earnings indicates an improvement of 10.4% from the year-ago figure. The same for revenues also implies growth of 5.3% from the prior-year reading. The consensus mark for RCMT&#39;s 2024 earnings has moved 2.2% north in the past 60 days.&nbsp;
The bottom line of AppLovin outpaced estimates in each of the last four quarters, the average surprise being 21.06%. The Zacks Consensus Estimate for APP&#39;s 2024 earnings is pegged at $3.46 per share, which indicates a nearly four-fold increase from the year-ago figure. The consensus mark for revenues implies growth of 35.2% from the year-ago actual. The consensus mark for APP&#39;s 2024 earnings has moved 13.1% north in the past 60 days.
Shares of Duolingo and AppLovin have gained 24% and 238.2%, respectively, year to date. However, RCM Technologies stock has lost 31% in the same time frame.
<a href="https://www.zacks.com/stock/news/2345644/western-union-expands-footprint-in-chile-with-khipu-partnership?cid=CS-BENZ-FT-analyst_blog|company_news_finance_sector-2345644">To read this article on Zacks.com click here.</a>

Latin America

Offerings

DUOL

RCMT

Western Union Expands Footprint in Chile With Khipu Partnership

OSTX

OS Therapies shares are trading higher after the company announced the completion of its Phase 2b clinical trial for OST+HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting to adjust protocol. It's data analysis and topline results are expected in Q4 2024.

Cryptocurrency markets are trading lower as geopolitical tensions continue to loom over global financial markets.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$60,619.33&nbsp;</td>
<td>&nbsp;-1%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,342.84&nbsp;</td>
<td>&nbsp;-3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$134.89</td>
<td>&nbsp;-5.8%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.103</td>
<td>&nbsp;-0.7%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.0000159</td>
<td>&nbsp;-3%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 13.4% and daily active addresses falling by 15.9%. Transactions greater than $100,000 are down from 9,410 to 8,750 &nbsp;in a single day. Exchanges netflows are down by 4,310.1%.</li>
<li>Coinglass data reports 93,852 traders were liquidated in the past 24 hours for $263.49 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41171878/franklin-templeton-seeks-sec-approval-for-dual-bitcoin-ethereum-index-etf">Franklin Templeton Seeks SEC Approval For Dual Bitcoin, Ethereum Index ETF</a></li>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41171711/visa-teams-up-with-bbva-to-issue-fiat-backed-tokens-on-blockchain-networks-plans-initial-pilot-b">Visa Teams Up with BBVA To Issue Fiat-Backed Tokens On Blockchain Networks, Plans Initial Pilot By 2025</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41170643/grayscale-launches-new-fund-for-aave-expands-investment-product-line">Grayscale Launches New Fund For AAVE, Expands Investment Product Line</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41159486/swift-targets-2025-to-test-digital-currency-trades-as-central-authorities-look-to-keep-pac">SWIFT Targets 2025 To Test Digital Currency Trades As Central Authorities Look To Keep Pace With Bitcoin&#8217;s Efficiency</a></li>
</ul>
Top Losers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Ethena (CRYPTO: ENA )</td>
<td>&nbsp;$0.2871</td>
<td>&nbsp;-13.8%</td>
</tr>
<tr>
<td>Beam (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/beam/usd">BEAM</a>)</td>
<td>&nbsp;$0.01479</td>
<td>&nbsp;-12.6%</td>
</tr>
<tr>
<td>Fantom (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ftm/usd">FTM</a>)</td>
<td>&nbsp;$0.6051</td>
<td>&nbsp;-9.9%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: With Bitcoin prices around the $60,000 mark, crypto chart analyst Ali Martinez marked $60,365 as the key Bitcoin level to watch. A break below this would take Bitcoin to $57,420. If this level holds, the crypto king will <a href="https://x.com/ali_charts/status/1841882152528486606">rebound</a> to $63,300, according to the analyst.
CryptoCon tweeted that the Bitcoin bull market starts in two months, according to their analysis.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The real <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> bull market begins in 2 months. November 28th, 2024. <a href="https://t.co/d3XHRviZTQ">pic.twitter.com/d3XHRviZTQ</a>
&mdash; CryptoCon (@CryptoCon_) <a href="https://twitter.com/CryptoCon_/status/1841871403567514106?ref_src=twsrc%5Etfw">October 3, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Santiment <a href="https://x.com/santimentfeed/status/1841889999463002294">data</a> pointed out that with Bitcoin dropping 9.2% since its $66,400 local high on Sep. 27, public sentiment towards crypto has cooled considerably. The analytics firm thinks this mood change is &#8220;encouraging, considering markets typically always move the opposite direction of the crowd&#8217;s expectation.&#8221;
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41166146/would-bitcoin-drop-if-a-war-in-the-middle-east-breaks-out-yes-but-theres-a-catch">Would Bitcoin Drop If A War In The Middle East Breaks Out? Yes, But There&#8217;s A Catch</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BEAM

$BTC

$DOGE

$ETH

$FTM

$SHIB

$SOL

Bitcoin, Ethereum, Dogecoin Drop Again, Continue Defying 'Uptober' Sentiments: Watch This Key Level For A Rebound To $63K, Says Analyst

Airline stocks have endured a <a href="https://www.benzinga.com/news/24/10/41124443/whats-going-on-with-delta-united-and-spirit-airlines-shares-tuesday">year of turbulence</a>, reflected by wild swings in share price, industry expectations and earnings. Recent insider trades of airline companies could indicate where the industry will head next.
The Trades: <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga Edge compiles information </a>on insider trade filings.
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) experienced a <a href="https://www.benzinga.com/markets/equities/24/10/41156975/southwest-airlines-director-rakesh-gangwal-invests-over-100m-in-shares-amid-elliott-managements-">flurry of insider activity</a> in recent days. Director Rakesh Gangwal invested over $100,000,000 in Southwest shares in late September and early October. Executive Chairman Gary C Kelly <a href="https://www.benzinga.com/quote/LUV/insider-trades">bought $1,000,000 of Southwest</a> shares in late September.
Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is the largest American airline company. The Atlanta-based giant experienced several insider sales in early 2024. President Glen W Hauenstein sold $4,904,600 in Delta stock in April, over 30% of his total holding. Executive Vice President Peter W Carter sold $2,500,000 of Delta shares that month, over 25% of his position.
Delta has experienced a volatile year. Its share price rose over 30% from January to mid-May, but a subsequent drawdown erased much of its gains. A recovery followed from August to late September.
Several Allegiant Travel Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGT#NASDAQ">ALGT</a>) executives <a href="https://www.benzinga.com/quote/ALGT/insider-trades">have sold shares</a> in 2024. Chief Marketing Officer Scott DeAngelo sold over $1,000,000 in Allegiant stock in May. DeAngelo has since <a href="https://ir.allegiantair.com/news/news-details/2024/Allegiant-Announces-Resignation-of-Executive-Vice-President-and-Chief-Marketing-Officer-Scott-DeAngelo/default.aspx">resigned</a> from the company. Chief Operating Officer Frank Wilper and Director Gary Ellmer also made sales in the spring and summer.
Why it Matters: Insider trading activity is often viewed as a valuable indicator of a company's future prospects. When top executives or board members buy or sell shares, it can signal their confidence—or lack thereof—in the company's performance. In the case of airline stocks, this insider movement may be especially relevant as the industry navigates a turbulent environment marked by fluctuating demand, rising fuel costs, and post-pandemic recovery.
For investors, tracking these insider trades provides a critical lens into how industry leaders perceive future risks and opportunities, which can guide their own strategies in an increasingly volatile market.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/general/sports/24/09/41053573/hurricane-helene-disrupts-flights-sports-events-disney-operations-affected-regions-stocks-to-watch">Hurricane Helene Disrupts Flights, Sports Events, Disney Operations: Affected Regions, Stocks To Watch</a></li>
</ul>
Photo: Tupungato/Shutterstock.com

Travel

Insider Trades

ALGT

Will Airlines Soar Or Stall? What Insider Trades Say About Industry's Future

TCBP

TC BioPharm shares are trading higher after the company announced an AI partnership with Carnegie Mellon University for donor screening.

Macquarie analyst Tim Nollen maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and raises the price target from $72 to $90.

ROKU

Macquarie Maintains Outperform on Roku, Raises Price Target to $90

Proficient Auto Logistics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares are trading higher on Thursday. Stifel analyst J. Bruce Chan reiterated a Buy rating on the stock <a href="https://www.benzinga.com/quote/PAL/analyst-ratings">with a price target of $21.00.</a>
The analyst writes that a prolonged port strike could pressure volumes at the company. While a backlog of under a week should be manageable this quarter, longer disruptions could extend impacts into 2025.
The auto-hauling sector offers greater yield benefits than the broader dry van truckload market, as ad hoc moves can command 2-3 times the average contract pricing, adds the analyst.
Chan says that while lower volume does create some negative operating leverage, its impact is less severe due to fewer lost backhauls and a smaller terminal network compared to LTL.
The analyst writes that Proficient&#8217;s stock has faced pressure recently due to an unexpected management departure, a weak third-quarter FY24 operating environment, and ongoing port strikes.
However, Chan notes the equity has overcorrected for these short-term disruptions, which should have minimal impact on 2025 valuations.
The analyst maintains 2024 and 2025 EPS estimates at $0.88 and $1.54, respectively.
Price Action: PAL shares are up 4.55% at $13.80 at the last check Thursday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41171072" target="_blank" rel="noreferrer noopener">Amazon Accused of Union-Busting After Drivers Unionize, NLRB Files Complaint</a></li>
</ul>

Proficient Auto Logistics Sees Stock Bounce Amid Short-Term Disruptions, Analyst Stays Bullish

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth keeping an eye on and we have a breakdown of all the biggest ones to watch on Friday!



Moving stocks are mergers, clinical trial data, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Crown LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock is rocketing almost 154% after <a href="https://finance.yahoo.com/news/crown-lng-holding-announces-completion-201700767.html">recently completing a business combination</a>.</li>



<li>Toyo (NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares are soaring close to 111% alongside heavy pre-market trading.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is surging over 60% with strong early morning trading.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) shares are increasing more than 42% without any clear news this morning.</li>



<li>Monterey Capital Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcac-stock-quote/">MCAC</a>) stock is gaining over 23% on Friday morning.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 19% with heavy early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is heading nearly 16% higher with strong pre-market trading.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are climbing over 15% with <a href="https://www.nasdaq.com/market-activity/stocks/immp/press-releases">positive clinical results</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is jumping more than 14% on Friday.</li>



<li>Instil Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/til-stock-quote/">TIL</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is crashing more than 44% on a <a href="https://www.nasdaq.com/press-release/shineco-announces-proposed-underwritten-public-offering-2024-07-11">proposed public offering</a>.</li>



<li>ASP Isotopes (NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) shares are diving over 19% as it also announces a <a href="https://www.globenewswire.com/news-release/2024/07/11/2912107/0/en/ASP-Isotopes-Announces-Proposed-Public-Offering-of-Common-Stock.html">proposed public offering</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is tumbling 18% following a <a href="https://www.nasdaq.com/press-release/more-1bn-annual-sales-alta-equipment-group-joins-cyngns-dealer-network-2024-07-11">massive rally yesterday</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">after rallying this week</a>.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/nano-nuclear-energy-announces-pricing-upsized-18-million-underwritten-offering-2024">pricing an upsized underwritten offering</a>.</li>



<li>Biodexa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) shares are falling more than 10% after jumping yesterday on <a href="https://seekingalpha.com/news/4123698-biodexa-stock-rallies-amid-release-of-phase-2-data-for-erapa">clinical trial data</a>.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) stock is dropping over 10% this morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are decreasing more than 10% following a Thursday rally.</li>



<li>Forward Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/ford-stock-quote/">FORD</a>) stock is dipping 10% without any news to report.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down over 9% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
If you&rsquo;ve read all the warnings and still want to jump into some of the top <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> to buy, focus on the key fundamentals.



That includes its earnings numbers, business models, product pipelines and what market they&rsquo;re part of.&nbsp;



You&rsquo;ll also want to pay close attention to volume, especially volume spikes. That&rsquo;s because volume often precedes price. In addition, you&rsquo;ll also want to see if the volume is being supported by news. Or you&rsquo;ll get what we just saw with Zapp Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>).



Over the last few days, ZAPP ran from about $2 to $19.10 on heavy volume &mdash; but no news.



On July 2, it traded at $2.04 and saw volume spike to 35.2 million, as compared to average volume of 7.2 million. On July 3, volume jumped to 25.5 million.



By July 5, it was up to 50.3 million. Then by July 8, volume soared to 105 million. And by July 9, volume was up 45 million. Now, as volume fades, the stock is starting to pull back.&nbsp;While it was fun to watch, it won&rsquo;t end well &mdash; especially for the stock-chasing bag holders.



Here are a few &ldquo;safer&rdquo; penny stocks to buy instead.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/03/pharmaceuticals_tnxp_1600-300x169.png" alt="medicine research, pharmaceutical background, LJPC stock"><div>Source: Sisacorn / Shutterstock.com</div></div>Keep an eye on penny stocks to buy such as Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>). Even after exploding from 20 cents to a high of $1.08, it could push aggressively higher.&nbsp;



All after it posted <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">positive Phase 2/3 results</a> for its drug paxalisib in the treatment of glioblastoma, which is a malignant tumor affecting the brain or spine. The study, called GBM-AGILE, showed a median overall survival of&nbsp;14.77 months for paxalisib-treated patients, as compared to 13.84 months for those given the standard of care.



With that, the company said it will request a meeting with the U.S. FDA to see if it can get accelerated approval.&nbsp;



As noted by <a href="https://www.biospace.com/article/releases/kazia-therapeutics-announces-phase-ii-iii-clinical-trial-results-for-paxalisib-in-glioblastoma/">Kazia CEO&nbsp;Dr.&nbsp;John Friend</a>, &ldquo;We are excited to have shown a 3.8-month improvement in overall survival, an approximate 33% improvement, for newly diagnosed unmethylated patients with GBM compared to the concurrent standard of care arm. Having comparable Overall Survival data across two independent studies is a compelling outcome in this difficult-to-treat glioblastoma population.&rdquo;



<h2>Curaleaf Holdings (CURLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/04/cannabis-stocks1600-3-300x169.png" alt="scientist checking organic hemp wild plants in a cannabis weed commercial greenhouse. Concept of herbal alternative medicine, cbd oil, pharmaceutical industry. Cannabis stocks, FLGC stocks"><div>Source: Chokniti-Studio / Shutterstock.com</div></div>At a bit over $4, Curaleaf Holdings (OTCMKTS:<a href="https://investorplace.com/stock-quotes/curlf-stock-quote/">CURLF</a>) is a strong buy on three key cannabis catalysts.



As I noted on July 8, &ldquo;We already know&nbsp;<a href="https://www.pewresearch.org/short-reads/2024/04/10/facts-about-marijuana/#:~:text=An%20overwhelming%20majority%20of%20U.S.,and%20recreational%20use%20(57%25).">88% of Americans</a>&nbsp;want legalization, which the current candidates should use to their advantage for votes. We know cannabis will be rescheduled as a Schedule III drug at some point.&nbsp;And we know that Florida will vote on legalization.&rdquo;



If Florida votes for legalization, it could unlock a massive market opportunity. All are potentially powerful catalysts.



Helping,&nbsp;<a href="https://www.newcannabisventures.com/curaleaf-q1-revenue/">according to Curaleaf CEO Matt Darin</a>, &ldquo;Our unique exposure to the most significant catalysts on the horizon &mdash; continued expansion of the NY market, expansion of Pillar 1 in&nbsp;Germany, and adult use in&nbsp;Ohio,&nbsp;Florida and&nbsp;Pennsylvania&nbsp;sets us up for robust growth in 2025 and beyond.&rdquo;



Last trading at around $4.16, I&rsquo;d use the recent weakness as an opportunity as we near the election.



<h2>Plug Power (PLUG)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/03/plug1600-7-300x169.png" alt="In this photo illustration, the Plug Power logo is displayed on a smartphone screen"><div>Source: rafapress / Shutterstock.com</div></div>We can also look at down, but not out shares of hydrogen stock, Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>).



After finding strong support at around $2.21, PLUG now trades at $3.02 and could push higher.&nbsp;Helping, the company just&nbsp;<a href="https://www.ir.plugpower.com/press-releases/news-details/2024/Plug-Completes-13-Hydrogen-Refueling-Station-Deployments-Over-Last-Two-Years-in-Europe/default.aspx#:~:text=SLINGERLANDS%2C%20N.Y.%2C%20July%2010%2C,last%20two%20years%20across%20Europe.">deployed 13 hydrogen refueling stations across Europe.</a> While most are still in the commissioning phase, all are expected to be operational this summer.



Even better, the company said it saw a &ldquo;<a href="https://seekingalpha.com/news/4092367-plug-power-touts-substantial-advancement-in-hydrogen-generation-buildout">substantial advancement</a>&rdquo; with its plants in Georgia and Tennessee. It also noted that its Louisiana joint venture with&nbsp;Olin&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/oln-stock-quote/">OLN</a>) is on track to see mechanical completion by the end of the third quarter.



Plus, it just signed&nbsp;<a href="https://www.globenewswire.com/news-release/2024/04/25/2869470/9619/en/Plug-Signs-Additional-BEDP-Contracts-for-a-Total-of-4-5GW-of-Electrolyzers-Across-Europe-and-the-United-States.html">two contracts</a>&nbsp;to deliver basic engineering and design packages for projects in Europe and the U.S.



Moreover, when and if we see changes to restrictive 45V industry tax credits, Plug Power and other top <a href="https://investorplace.com/industries/energy/renewable-energy/hydrogen/">hydrogen stocks</a> could race to higher highs.



On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.



Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>



On the date of publication, Ian Cooper did not hold (either directly or indirectly) any positions in the securities mentioned. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/?utm_source=Nasdaq&amp;utm_medium=referral">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Ian Cooper, a contributor to InvestorPlace.com, has been analyzing stocks and options for web-based advisories since 1999.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/07/from-pennies-to-dollars-3-sub-5-stocks-set-to-explode-higher/">From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biotechnology stock traders, listen up! Do you like to roll the dice and take your chances on promising drug developers? If so, then you&rsquo;ll definitely want to add Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) to your watch list. I can&rsquo;t guarantee any safety whatsoever, but Kazia Therapeutics stock offers excitement and the possibility of substantial profits.



Or, Kazia Therapeutics might not secure full regulatory approval for its primary product, and the stock could go nowhere or just go to zero. Nearly any outcome is plausible in the wild world of <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a>. So, I invite you to discover Kazia Therapeutics and decide if your stomach can handle the volatility and unpredictability.



<h2>Why Kazia Therapeutics Stock Went Bananas</h2>



Just to recap, Australian biotechnology business Kazia Therapeutics develops oncology (cancer and tumor fighting) drugs. One of Kazia Therapeutics&rsquo; drug-development programs is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">EVT801</a>. This was found in preclinical research to be &ldquo;active against a broad range of tumour types.&rdquo;



Not to discount the importance of EVT801, but Kazia Therapeutics&rsquo; primary drug in development is <a href="https://finance.yahoo.com/news/kazia-therapeutics-announces-phase-ii-113000064.html">paxalisib</a>. Recently, Kazia Therapeutics completed a phase II/III study of paxalisib in the treatment of a type of brain cancer type called glioblastoma.



Kazia Therapeutics CEO John Friend&nbsp;proudly announced the results of the clinical trial. Paxalisib demonstrated a &ldquo;3.8 month improvement in overall survival, an approximate 33% improvement&rdquo; for selected glioblastoma patients when &ldquo;compared to the concurrent standard of care arm.&rdquo;



Furthermore, Kazia Therapeutics was well tolerated in the study. Thus, this is huge news for Kazia Therapeutics as paxalisib is the company&rsquo;s flagship product.



Kazia Therapeutics stock skyrocketed from 20 cents per share to a 52-week high of $1.58. However, the stock then sank to 53 cents. By the time you read this, the share price may be much higher or lower than that.



<h2>What&rsquo;s Next for Kazia Therapeutics?</h2>



I expect the Kazia Therapeutics share price to level off as the buyers and sellers start to calm down in the coming days. Going forward, investors should consider what&rsquo;s next for Kazia Therapeutics and paxalisib.



Two events could be make-or-break for Kazia Therapeutics. First of all, Kazia Therapeutics expects to release the full data from the paxalisib research study &ldquo;at a scientific meeting later this year.&rdquo; Heaven only knows when this will actually take place, so I won&rsquo;t attempt to make any predictions.



Kazia Therapeutics stated that it will request a meeting with the U.S. Food and Drug Administration to &ldquo;discuss the results and determine if a potential path to accelerated approval is appropriate for paxalisib.&rdquo; 



Full FDA approval is the gold standard for proposed drugs in the U.S., so keep an eye out for further developments on this news story.



<h2>Kazia Therapeutics Stock: Predict Nothing and Protect Your Wealth</h2>



Some stock traders probably enjoyed quick gains after Kazia Therapeutics released its positive clinical-trial results. Yet, some ill-timed traders may have lost money. It just goes to show that biotech stocks can be highly unpredictable and risky.



Hence, I don&rsquo;t recommend trying to predict with 100% confidence whether Kazia Therapeutics will get full FDA approval for paxalisib in treating glioblastoma patients. 



Instead, if you appreciate the company&rsquo;s promising clinical work, consider buying Kazia Therapeutics stock. At the same time, be sure to protect your wealth by only taking a very small share position.



On the date of publication, David Moadel&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<div>David Moadel has provided compelling content &ndash; and crossed the occasional line &ndash; on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/biotech-stock-laboratory-try-a-small-experiment-with-kazia-therapeutics/">Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Australian biotech company Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) stock rocked the market after reporting encouraging results from a Phase II/III trial for its glioblastoma brain cancer therapy Paxalisib.&nbsp;



The positive results extended the life of patients by over three months compared to the current standard of care. Because the patients were a difficult-to-treat population, the results gave the oncology biotech developer cause to arrange a meeting with the Food &amp; Drug Administration (FDA) to pursue an accelerated pathway for approval.



As a result, Kazia Therapeutics stock surged 730% on the news, jumping from 19 cents per share to as high as $1.58 before eventually tumbling lower. Shares stand 110% above where they traded before it posted the results.



Because glioblastoma treatment is seen as a <a href="https://www.pharmiweb.com/press-release/2024-03-25/glioblastoma-treatment-market-expected-to-reach-usd-103-billion-by-2032-marketresearchbiz">$10 billion market opportunity</a> according to some estimates, producing a treatment that is better than the current level of care is a major achievement.&nbsp;



As such, there are numerous avenues for Kazia Therapeutics to exploit this market if Paxalisib gains approval. What can&rsquo;t be ignored is the possibility a pharmaceutical giant that is looking to bolster its portfolio of oncology drugs could step up and acquire Kazia Therapeutics stock.



<h2>A New Lease on Life</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/cells-microscope-300x169.png" alt="An image of cells under a microscope"><div>Source: pinkeyes/Shutterstock</div></div>Glioblastoma (GBM) is reportedly <a href="https://www.aans.org/patients/conditions-treatments/glioblastoma-multiforme/">one of the most common</a> and aggressive forms of brain cancer. It represents nearly half of all brain cancers. Tumors form in the brain or spinal cord though they most often occur in the frontal and temporal lobes. Left untreated, GBM can be fatal in six months or less.



Kazia Therapeutics&rsquo; Paxalisib is its<a href="https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-phase-iiiii-clinical-trial-results-for-paxalisib-in-glioblastoma-302193414.html"> lead drug candidate</a> and has been the subject of 10 clinical trials for this disease. The FDA previously granted the therapy Orphan Drug status in 2018 and it gained fast-track designation in 2020. It has received various other designations from the regulatory authorities for various diseases.



In the Phase II/III study, Paxalisib resulted in a median survival rate of over 15.5 months compared to 11.9 months under the current standard of care. This is in line with an earlier Phase II study that found similar longevity by administering Paxalisib.



<h2>A Hotbed of M&amp;A Activity</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/10/mergers-acquisitions-300x169.jpg" alt='The letters "M&amp;A" on a wooden table, surrounded by a calculator and other business items. Representing IEA stock.'><div>Source: Shutterstock.com</div></div>According to analysts at White &amp; Case, the field of oncology is setting a fire underneath mergers and acquisitions. Dealmaking will <a href="https://mergers.whitecase.com/highlights/oncology-dealmaking-fuels-biotech-ma#!">reach $375 billion</a> in 2027 as demand for treatments grows.



In less than a year, Bristol Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) acquired Mirati Therapeutics for $5.8 billion to gain possession of its <a href="https://investorplace.com/2024/06/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet/">lung cancer treatment</a>. It also paid $800 million upfront to China&rsquo;s SystImmune for its signal-blocking therapy for cancer cells. It could be worth up to $8.4 billion.



AbbVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/abbv-stock-quote/">ABBV</a>) also <a href="https://investorplace.com/2024/04/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher/">acquired ImmunoGen for $10 billion</a> and Johnson &amp; Johnson (NYSE:<a href="https://investorplace.com/stock-quotes/jnj-stock-quote/">JNJ</a>) bought Ambrx Biopharma for $2 billion. Previously, AstraZeneca (NYSE:<a href="https://investorplace.com/stock-quotes/azn-stock-quote/">AZN</a>), Gilead Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/gild-stock-quote/">GILD</a>) and Merck (NYSE:<a href="https://investorplace.com/stock-quotes/mrk-stock-quote/">MRK</a>) all made acquisitions in the cancer space to shore up their portfolios.



As patent expirations approach a critical stage for pharmaceutical stocks, Kazia Therapeutics could gain attention for Paxalisib.



<h2>Still a Risky Bet</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/08/doctor_medicine_dna_1600-300x169.jpg" alt="Various graphical representations of medical imagery are shown in front of a doctor using a tablet computer. DNA stock"><div>Source: Shutterstock / PopTika</div></div>Kazia Therapeutics stock has now traded in the 40-cent per share range for several days. Most of the gains were wrung out of the stock immediately after the results were published.



There could be a more massive upside in KZIA shares. Yet it still has the late-stage trials to go through, gaining permission from the FDA for fast-track approval and ultimately getting marketing approval.



Each step could excite the stock market again if the results are just as positive. Arguably staking a small claim to Kazia Therapeutics stock isn&rsquo;t a bad idea. I wouldn&rsquo;t go all-in because biotech investing is risky and full of unknowns. But for the speculative portion of your portfolio, buying a small tranche of the stock might not be a bad idea.



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making/">Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While investing in the best&nbsp;<a href="https://investorplace.com/stock-types/blue-chip-stocks/" target="_blank">blue chip stocks</a>&nbsp;to anchor your portfolio is always a good idea, I am always looking to diversify. A good way to do that is to invest in lesser-known but quality stocks under $10.



Lower-priced stocks have the advantage of being affordable so that you can buy more shares with less money. It&rsquo;s much cheaper to buy 100 shares of a $5 stock than to buy the same number of shares of an equity that cost $100 or more, right?



And these lower-priced stocks still can outperform the market. While the risks are higher, the rewards can be substantial, offering a tempting opportunity for investors willing to take on some level of risk.



I always suggest using the Portfolio Grader to help find the best stocks under $10. In fact, using a stock screening tool is essential in an exercise such as this.



Why? Because there are over&nbsp;<a href="https://money.usnews.com/investing/stocks/search?price-min=0&amp;price-max=10" target="_blank">2,100 stocks</a>&nbsp;on the market today are&nbsp;priced at $10 or less. No one can identify all of the best-performing stocks &ndash; or those that have the potential to perform &ndash; without using a screener like the Portfolio Grader to narrow the field.



The Portfolio Grader evaluates stocks based on various measurements, including earnings performance, growth, analyst sentiment, and momentum. The stocks under $10 on this list all score well enough to get at least a &ldquo;B&rdquo; rating in the Portfolio Grader tool.



<h2>Faraday Future Intelligent Electric (FFIE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/07/ffie1600-1-300x169.png" alt="Person holding cellphone with logo of electric vehicle company Faraday Future Inc. (FFIE) on screen in front of business webpage. Focus on phone display. Unmodified photo."><div>Source: T. Schneider / Shutterstock.com</div></div>Faraday Future Intelligent Electric (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) designs, manufactures and sells electric vehicles and related products. The California company operates in the United States and China.



The company has gotten into some hot water with Nasdaq and its listing requirements because the stock is less than $1 &ndash; it has until Aug. 31 to get the stock price up &ndash; and for not always promptly filing financial reports. 



Those are red flags for sure, so already you know FFIE stock is a speculative play.



Although revenue in 2023 was only $800,000, it was the company&rsquo;s first year of revenue, as it&rsquo;s still very much a startup. Faraday delivered its first-ever vehicles in the third quarter of the year.



However, Faraday also has some interesting things in the works, as outlined in its <a href="https://investors.ff.com/news-releases/news-release-details/faraday-future-hosts-investor-community-day-and-highlights">July 20 Investor Day event</a>. Highlights included a look at the All-Ability aiHypercar, its user ecosystem, and the company&rsquo;s Auto Industry Bridge strategy.



The company raised the idea of launching a second, lower-priced automotive brand. &ldquo;A second brand could strike in the mass market with volume production, bringing everyone the &lsquo;AI car of the future&rsquo; and the &lsquo;AI car of the people&rsquo;. 



We are preparing to launch the Bridge and second brand strategies in a future event where we will share more details and our progress. We are hopeful to set sail together in the blue ocean market with potential partners,&rdquo;&nbsp;founder YT Jia said.



The company scheduled a July 31 shareholder vote that includes a proposal for a 1-for-40 reverse stock split to maintain its Nasdaq compliance. For now, FFIE stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>SoundHound AI (SOUN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/02/soun1600-1-300x169.png" alt="In this photo illustration, the SoundHound logo seen displayed on a smartphone. SOUN stock"><div>Source: rafapress / Shutterstock.com</div></div>SoundHound AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/soun-stock-quote/">SOUN</a>) is an up-and-coming technology company that is using artificial intelligence and machine learning to create products that recognize and respond to verbal prompts.



SoundHound&rsquo;s platform is used by restaurants to <a href="https://investors.soundhound.com/news-releases/news-release-details/beef-o-bradys-rolls-out-soundhounds-advanced-voice-ai-ordering">automate food ordering</a>, reducing employee costs. Through its Dynamic Interaction platform, customers can verbally place complicated orders at a kiosk and pay without the intervention of an employee.



Another interesting use of SoundHound&rsquo;s platform is its employee training. Inexperienced workers can use SoundHound to ask questions about a process and SoundHound&rsquo;s AI will answer intelligently and walk the employee through the proper steps.



SoundHound also has a product that has a <a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-chat-ai-launches-peugeot-opel-and-vauxhall-vehicles">Chat AI product</a> &ndash; integrated with ChatGPT &ndash; that can manage navigation, advise about the weather or tell stories to bored children in the back seat.



I also like that SoundHound is shoring up its financial position. The company <a href="https://finance.yahoo.com/news/soundhound-ai-announces-early-debt-130000956.html">announced</a> that it reached an agreement with lenders to repay $100 million in outstanding debt. Once that&rsquo;s done, SoundHound will have zero debt and a cash balance of $180 million.



<a href="https://investors.soundhound.com/news-releases/news-release-details/soundhound-ai-reports-73-q1-revenue-growth-116-million-first">Revenue in the first quarter</a>&nbsp;was $11.6 million, up 73% from a year ago. And with a subscription and booking backlog of $682 million, up 80% from just a year ago, I think SoundHound will start turning a profit soon.



SOUN stock gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Kazia Therapeutics (KZIA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) is an Australian oncology company that&rsquo;s developing therapies for brain, liver and renal cancers.



The company&rsquo;s lead program is paxalisib, which is currently in Phase 3 trials as a treatment for glioblastoma, which is an aggressive form of brain cancer. Paxalisib is also in Phase 2 trials as a treatment for childhood brain cancers, brain metastases, and non-Hodgkin&rsquo;s lymphoma.



The stock had massive gains this month when it announced <a href="https://investorplace.com/2024/07/why-is-kazia-therapeutics-kzia-stock-up-300-today/">positive results</a> for paxalisib&rsquo;s glioblastoma trial. The company reported that patients who received paxalisib had a median overall survival period of 14.77 months, compared to 13.84 months for patients who did not receive the drug.



In a prespecified secondary analysis, the survival period for paxalisib patients was 15.54 months compared to 11.89 months for patients who did not take the drug.



Investing in biotech and pharma stocks can be very challenging because there&rsquo;s a lot of research &ndash; and a lot of expense &ndash; before a drug can even go to regulators for possible approval. But Kazia&rsquo;s work appears to be promising, and that&rsquo;s driving the momentum of KZIA stock right now.



Kazia stock is up 40% over the last month, and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Koss (KOSS)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/koss1600-300x169.png" alt="Koss Porta Pro Wireless headphones on a round case like on your head on a white background with reflection"><div>Source: PhotOleh / Shutterstock.com</div></div>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) is a manufacturer of headphones and accessories such as earbuds, electrostatic headphones and audio products for health care and education.



The company has been around for more than 60 years and came to renewed prominence in recent years as a popular meme stock. The meme factor makes Koss a volatile stock &ndash; shares jumped <a href="https://investorplace.com/2024/07/koss-stock-alert-koss-surges-90-on-renewed-meme-interest/">90% earlier this month</a> on speculative short-seller interest.



Earnings for the company&rsquo;s fiscal third quarter (ending March 31) showed weakening performance. Sales of $2.6 million was down from $3.3 million in the same quarter a year ago. Profits of $841,000 were down from $1.3 million on a year-over-year basis.



Koss is purely a meme stock play and should be treated with a lot of caution. If the stock jumps again &ndash; and odds are that it will &ndash; it would be wise to take profits at the peak.



KOSS stock is up 171% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>VivoPower International (VVPR)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/05/electric-vehicle-ev-stocks-charging-black-neon-1600-300x169.jpg" alt="Electric car backlit by cyan blue neon light next to EV charger with cyan blue light and lightning bolt symbol, all against a black background. ev stocks to buy"><div>Source: shutterstock.com/JLStock</div></div>VivoPower International (NASDAQ:<a href="https://investorplace.com/stock-quotes/vvpr-stock-quote/">VVPR</a>) is an international battery technology and electric vehicle services company headquartered in the U.K. The company also operates in Australia, Canada, the Netherlands, the Philippines, the UAE and the U.S.



The company is preparing for a <a href="https://finance.yahoo.com/news/vivopower-announces-binding-heads-agreement-151900389.html">merger of its subsidiary</a>, Tembo E-LV, with Cactus Acquisition Corp. 1 Limited (NASDAQ:<a href="https://investorplace.com/stock-quotes/cctsw-stock-quote/">CCTSW</a>), a special purpose acquisition company in preparation for taking Tembo public. Tembo, which is an electric vehicle services company in the Netherlands. 



Following the merger, the new Tembo Group expects to be publicly traded on the Nasdaq exchange. The new company would have a valuation of $838 million, with VivoPower shareholders receiving 20% of the company.



Thus, VVPR stock is an interesting bet on EVs with heavy European exposure. VivoPower stock is up 37% this year and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>Soligenix (SNGX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/07/sngx1600-300x169.png" alt="Soligenix is a leading biopharmaceutical firm developing drugs for rare diseases. It's renowned for solutions in oncology biodefense fields. SNGX stock"><div>Source: MacroEcon / Shutterstock.com</div></div>Soligenix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/">SNGX</a>) is a U.S. biopharmaceutical company that is working on a variety of products. It currently has several drug candidates in advanced stages of trials, including a treatment for early-stage cutaneous T-cell lymphoma in Phase 3 testing.



Soligenix has other Phase 2 tests underway for psoriasis, oral mucositis, and pediatric Crohn&rsquo;s disease.



But it&rsquo;s the early-stage cutaneous T-cell lymphoma trial that has investors excited. The stock jumped nearly 300% earlier this month &ndash; before giving some of those gains back &ndash; following a study testing HyBryte as a treatment). 



Six patients are enrolled in the yearlong study, with four of them completing at least 12 weeks of treatment. Of those, Soligenix says three patients already achieved treatment success, which is a 50% improvement in their cumulative mCAILS score compared to baseline. The fourth patient also saw improvement, the company said.



While this is a positive development, it&rsquo;s important to recognize that HyBryte is still a long way from making it to regulatory approval. But as a speculative play, SNGX stock has potential.



The stock is up 48% in the last month and has a &ldquo;B&rdquo; rating in the Portfolio Grader.



<h2>First Foundation (FFWM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/05/piggy-bank-grad-300x169.jpg" alt="A pink piggy bank wearing a grad cap sits on a wooden table in front of a chalkboard."><div>Source: Shutterstock</div></div>First Foundation (NYSE:<a href="https://investorplace.com/stock-quotes/ffwm-stock-quote/">FFWM</a>) is a regional bank that&rsquo;s headquartered in Dallas, but has offices in California, Florida, Hawaii, Nevada and Texas.



The bank has $13.6 billion in assets as well as $10.1 billion of loans, deposits of $10.6 billion and stockholder equity of $929 million.



It also just completed an <a href="https://investor.ff-inc.com/news/news-details/2024/First-Foundation-Inc.-Closes-228-Million-Equity-Investment-Anchored-by-Fortress-Investment-Group-Canyon-Partners-Strategic-Value-Bank-Partners-and-North-Reef-Capital/default.aspx">investment deal</a> with several investment firms, including Fortress Investment Group, Canyon Partners, Strategic Value Bank Partners and North Reef Capital that injected $228 million into the company. First Foundation issued 11.3 million shares of stock valued at $4.10 each as part of the transaction.



The company is reporting second-quarter earnings on July 25, with <a href="https://investorplace.com/2024/07/why-is-first-foundation-ffwm-stock-down-27-today/">analysts expecting</a> flat adjusted earnings per share as well as revenue of $54.48 million. A year ago in the second quarter, FFWM saw $61.1 million in revenue and earnings of 7 cents per share.



Regional banking stocks have been challenging investments for the last few quarters, but FFWM appears to be on an upswing. The stock is up 25% in the last month and gets a &ldquo;B&rdquo; rating in the Portfolio Grader.



On the date of publication, neither Louis&nbsp;Navellier nor the InvestorPlace Research Staff member primarily responsible for this article held (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://url.us.m.mimecastprotect.com/s/AAadCPNlWWs3yKYns0yRM6?domain=investorplace.com/">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) and positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/market360/2024/07/7-top-stocks-under-10-july-2024-edition/">7 Top Stocks Under $10: July 2024 Edition</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Top Stocks Under $10: July 2024 Edition

Kazia Therapeutics files to sell $100M of American Depositary Shares

Kazia Therapeutics enters into licensing agreement with QIMR Berghofer

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has secured an exclusive worldwide license from QIMR Berghofer Medical Researc...

Kazia Therapeutics Advances Cancer Treatment Options

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics presented promising data from a Phase 1 trial of EVT801, showing potential as ...

Kazia Therapeutics Reveals Hopeful Ovarian Cancer Study

Kazia Therapeutics (KZIA) has released an update. Kazia Therapeutics has unveiled encouraging Phase I study results at the ASTRO 2024, showing that...

Kazia Therapeutics Reveals Promising Brain Cancer Study

ABBV

ABVE

ASPI

BDRX

CCTSW

CGBS

CURLF

DBGI

FFIE

FORD

GILD

IMMP

KOSS

KZIA

MAXN

MCAC

NUWE

PLUG

QLGN

SISI

SNGX

SNOA

SNTG

SOUN

TOYO

VVPR

ZAPP

Press Releases

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Biotech Experiences Strong Open Following Major Announcement

Citius Pharmaceuticals (CTXR) Nears Key FDA Decisions and Launch Plans for 2024

Citius Pharmaceuticals (CTXR) Eyes Breakthrough with Late-Stage Drug Pipeline Poised for Regulatory Approval

KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER

Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium

Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting

Comments

Kazia Therapeutics

Interés en corto

Kazia Therapeutics (NASDAQ:KZIA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL